Valuation: SenzaGen AB

Market Cap 161M 16.29M 14.61M 13.35M 12.19M 22.96M 1.53B 23.68M 64.16M 817M 61.13M 59.82M 2.58B P/E 2024
-10.5x
P/E 2025 -15.5x
Enterprise Value 153M 15.49M 13.89M 12.69M 11.59M 21.83M 1.46B 22.52M 61.01M 777M 58.13M 56.88M 2.45B EV / Sales 2024
2.87x
EV / Sales 2025 2.96x
Free-Float
76.39%
Yield 2024 *
-
Yield 2025 -
1 day+2.27%
1 week+1.85%
Current month+1.85%
1 month+10.00%
3 months-6.25%
6 months-11.29%
Current year-18.59%
1 week 4.66
Extreme 4.66
5.18
1 month 4.21
Extreme 4.21
5.38
Current year 4.21
Extreme 4.21
6.4
1 year 4.21
Extreme 4.21
6.7
3 years 3.86
Extreme 3.86
9.8
5 years 3.86
Extreme 3.86
14.45
10 years 3.86
Extreme 3.86
74
Manager TitleAgeSince
Chief Executive Officer 52 2021-08-18
Director of Finance/CFO 65 2016-10-31
Chief Operating Officer 44 2013-12-31
Director TitleAgeSince
Chairman 78 2014-12-31
Director/Board Member 61 2019-06-16
Director/Board Member 76 2014-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/20 Buy

Chief Executive Officer

25,000 0.1171%
9/1/20 Buy

Chief Executive Officer

480 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
+2.27%+1.85%-17.77%-27.84% 16.29M
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average +1.24%+2.57%+42.49%+164.61% 40.67B
Weighted average by Cap. +0.65%+3.07%+49.90%+165.87%

Financials

2024 2025
Net sales 57.7M 5.84M 5.24M 4.79M 4.37M 8.23M 549M 8.49M 23.01M 293M 21.92M 21.45M 925M 57.97M 5.87M 5.26M 4.81M 4.39M 8.27M 552M 8.53M 23.12M 294M 22.02M 21.55M 929M
Net income -17.85M -1.81M -1.62M -1.48M -1.35M -2.55M -170M -2.63M -7.12M -90.62M -6.78M -6.64M -286M -11.59M -1.17M -1.05M -961K -878K -1.65M -110M -1.71M -4.62M -58.82M -4.4M -4.31M -186M
Net Debt -37.83M -3.83M -3.43M -3.14M -2.86M -5.4M -360M -5.57M -15.08M -192M -14.37M -14.06M -606M -7.91M -801K -718K -656K -599K -1.13M -75.28M -1.16M -3.15M -40.17M -3.01M -2.94M -127M
Projected Income Statement - Annual - SenzaGen AB
Logo SenzaGen AB
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Employees
34
Date Price Change Volume
26-11-06 SEK 4.950 +2.27% 25,836
26-11-05 SEK 4.840 +1.47% 89,462
26-11-04 SEK 4.770 -3.44% 18,121
26-11-03 SEK 4.940 -1.98% 13,378
26-11-02 SEK 5.040 +3.70% 48,667

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - SenzaGen AB
  1. Stock Market
  2. Stocks
  3. SENZA Stock